Biopharma revolutionaries lead the way as the pharmaceutical sector edges towards Industry 4.0
As the fourth industrial revolution gathers pace across the globe, leading pharmaceutical companies are driving innovation by deploying the internet…
Accelerating Biopharmaceutical Innovation
In association with Cytiva
Buy or build: Strategies to meet demand for vaccine and viral vector production
In the mid-20th century, the successful development and large-scale production of vaccines for a range of life-threatening diseases completely revolutionised…
Latest News
View More
Strategies to address the viral vector manufacturing shortage
With the exciting promise of addressing previously unmet medical needs, the rapidly growing field of gene therapy has already begun to revolutionize patient treatment. The…
Viral vector manufacturing: design considerations to improve commercial success
Viral vector manufacturing: the key to the success of gene therapy Frost & Sullivan recently invited industry thought leaders working in the viral vector manufacturing…
A standard approach to drug development for accessing the globe
Standardization in business requires us to take a step back from the belief that our technology and processes are unique…
Developing a new biologic drug: regulatory challenges and considerations
The journey from research lab to market is a long one, and most drug candidates do not make it. For…
Implementing the ballroom concept for biomanufacturing: Lessons, reflections and considerations from experience
The ballroom concept was originally defined in the International Society of Pharmaceutical Engineers (ISPE) Baseline Guide: Volume 6 - Biopharmaceutical…
